Key result
Septal late gadolinium enhancement predicted major adverse cardiovascular events at 1 year in patients with ICI-induced myocarditis (adjusted HR 2.7; 95% CI 1.1-6.7; P=0.03).
Why the study?
Cardiac MRI features are not well-defined in immune checkpoint inhibitor-induced myocarditis, a severe complication of ICI therapy in patients with cancer.
What are the distinct cardiac MRI features of immune checkpoint inhibitor-induced myocarditis, and does cardiac MRI predict major adverse cardiovascular events in these patients?
Population
33 patients with ICI-M, 21 cancer patients scheduled for ICI, and 85 with viral myocarditis
Comparison
Patients with ICI-M vs pre-ICI cancer patients vs viral myocarditis patients
Design
Retrospective study
Follow-up
1 year
Authors
Loading...
Septal LGE may aid risk stratification in ICI-myocarditis; leaves open whether CMR findings should guide therapy or improve outcomes.
Observational (n=139)
What are the distinct cardiac MRI features of immune checkpoint inhibitor-induced myocarditis, and does cardiac MRI predict major adverse cardiovascular events in these patients?
Hazard Ratio: 2.7 (95% CI 1.1–6.7)
p-value: p=0.03
Cardiac MRI reveals distinct features in ICI-induced myocarditis compared to viral myocarditis, and the presence of septal late gadolinium enhancement is a significant predictor of 1-year major adverse cardiovascular events.
Cadour et al. (2022) conducted an observational in Immune checkpoint inhibitor-induced myocarditis (n=139). Septal late gadolinium enhancement (LGE) vs. Absence of septal LGE was evaluated on Major adverse cardiovascular events (MACE) at 1 year (adjusted HR 2.7, 95% CI 1.1-6.7, p=0.03). Septal late gadolinium enhancement predicted major adverse cardiovascular events at 1 year in patients with ICI-induced myocarditis (adjusted HR 2.7; 95% CI 1.1-6.7; P=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: